Copenhagen, 2012-05-09 11:24 CEST (GLOBE NEWSWIRE) -- Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S shall announce transactions in the company’s shares and related securities by executives and persons/companies closely related to them. In this regard, Zealand Pharma announces the following transactions: Name: Mats Blom ----------------------------------------------------------------------------- Reason: Senior Vice President and Chief Financial Officer ----------------------------------------------------------------------------- Issuer: Zealand Pharma A/S ----------------------------------------------------------------------------- Type Shares ----------------------------------------------------------------------------- ISIN code: DK0060257814 ----------------------------------------------------------------------------- Transaction: Sale ----------------------------------------------------------------------------- Trading date: 7 and 8 May 2012 ----------------------------------------------------------------------------- Market: NASDAQ OMX København A/S ----------------------------------------------------------------------------- Amount (number of shares): 22,959 ----------------------------------------------------------------------------- Price: DKK 106.20 ----------------------------------------------------------------------------- Market value: DKK 2,438,316 ----------------------------------------------------------------------------- Name: John Hyttel ----------------------------------------------------------------------------- Reason: Senior Vice President and Chief Operating Officer ----------------------------------------------------------------------------- Issuer: Zealand Pharma A/S ----------------------------------------------------------------------------- Type Shares ----------------------------------------------------------------------------- ISIN code: DK0060257814 ----------------------------------------------------------------------------- Transaction: Sale ----------------------------------------------------------------------------- Trading date: 8 May 2012 ----------------------------------------------------------------------------- Market: NASDAQ OMX København A/S ----------------------------------------------------------------------------- Amount (number of shares): 24,000 ----------------------------------------------------------------------------- Price: DKK 101.80 ----------------------------------------------------------------------------- Market value: DKK 2,443,200 ----------------------------------------------------------------------------- Hereafter, Mats Blom owns 90,246 shares and 98,031 warrants and John Hyttel owns 122,454 shares and 98,031 warrants in Zealand Pharma A/S. ### For further information, please contact: David Horn Solomon, President and Chief Executive Officer Tel: +45 2220 6300 Hanne Leth Hillman, Vice President for IR & Corporate Communication Tel: +45 5060 3689, email: hlh@zealandpharma.com About Zealand Pharma Zealand Pharma A/S (NASDAQ OMX: ZEAL) is a biotechnology company based in Copenhagen, Denmark with a mature clinical pipeline of innovative peptide drugs. The company's lead invention is lixisenatide (Lyxumia® 1)), a once-daily GLP-1 agonist, licensed to Sanofi for the treatment of Type 2 diabetes. In November 2011, Sanofi filed for registration of lixisenatide in Europe and regulatory filing in the United States is expected in Q4 2012. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering dual acting glucagon/GLP-1 agonists, including ZP2929, for the treatment of diabetes and obesity, and a license agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the prevention of chemotherapy-induced diarrhea. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs, and all drug candidates in its pipeline have been identified through the company's own drug discovery activities. Zealand Pharma's products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com. Note 1) Lyxumia® is the intended trademark for lixisenatide. Lixisenatide is not currently approved or licensed anywhere in the world.